# A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

> **NCT01928615** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 2 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab - intravenous solution
- **DRUG:** Trastuzumab - subcutaneous solution
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT01928615
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Problems with drug supply
- **Last updated:** 2014-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928615, "A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01928615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*